HEMLIBRA Subcutaneous injection General Drug Use Surveillance(in Hemophilia A with Inhibitors)
Phase of Trial: Phase IV
Latest Information Update: 09 Nov 2019
Price : $35 *
At a glance
- Drugs Emicizumab (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical
- 22 May 2018 Status changed from planning to recruiting.
- 27 Mar 2018 New trial record
- 23 Mar 2018 According to a Chugai Pharmaceutical media release, results of the surveillance will be reported to the regulatory authorities, and the data shall be announced at future scientific meetings.